Nxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Thu 07:31
BRIEF-Nxera Pharma Co., Ltd.- Nxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy Oct 22 (Reuters) - Nxera Pharma Co., Ltd. 4565.T:
NXERA PHARMA CO., LTD.: NXERA PHARMA SUBMITS MARKETING AUTHORIZATION APPLICATION FOR VAMOROLONE IN SOUTH KOREA FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
NXERA PHARMA CO., LTD.: TARGETING MARKETING AUTHORIZATION IN SOUTH KOREA IN 2027, FOLLOWED BY A COMMERCIAL LAUNCH IN 2028
Source text: ID:nTSvv8768d
Further company coverage: 4565.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up